Trial
NCT04171219
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Advanced Malignant Solid Neoplasm
Intervention
Pembrolizumab
Why stopped
There is no PR/CR observed in the first stage, so study stopped without proceeding to the stage 2 of efficacy stage.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16